LOS ANGELES: After decades of warning the public that vested interests were burying psychiatric drug risks, vehemently denied by the psychiatric/pharmaceutical industires, the mental health watchdog Citizens Commission on Human Rights (CCHR) says new research published Jan 17 in the New England Journal of Medicine vindicates their demands for full public disclosure.
CCHR has filed Freedom of Information requests to the Food and Drug Administration (FDA) for adverse reactions reports of antidepressants, helped to orchestrate FDA hearings into the suicidal side effects of antidepressants and filed complaints to government officials and agencies about the conflicts of interest of FDA advisory committee members ignoring the drugs' side effects. In addition, CCHR has issued numerous publications about the cover-up of psychiatric drug side effects and has filed complaints worldwide with licensing boards and other agencies on behalf of people harmed by psychiatric drugs including stimulants, antidepressants and antipsychotics.
Now, a new report in the New England Journal of Medicine entitled, “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy,” has revealed that negative studies on antidepressants are either not being published, or are skewed in a way that makes them appear positive. (See stories running on Fox National News, The New York Times, and The Wall Street Journal) CCHR says the psychiatric-pharmaceutical cartel is not only misleading the public about the drugs, but also about the disorders for which they are prescribed.
Just this month, U.S. News and World Report confirmed that the American Psychiatric Association (APA) failed to fully disclose the substantial pharmaceutical ties of its task force members, charged with updating and expanding psychiatry’s Diagnostic and Statistical Manual of Mental Disorders, comprised of subjective checklists of symptoms which are then used to categorize new “mental disorders” and bill insurance companies. Even high-ranking psychiatrists such as Steven Sharfstein, former president of the APA, have pointed out the financial corruption in their field. In 2006, Sharfstein admitted, “We have allowed ourselves to be corrupted in this marketplace with lucrative consulting to industry, speaker panels, boards of directors and visits from industry representatives bearing gifts.”
For more information on the financial ties between psychiatrists and drug manufacturers, read CCHR’s publication, Psychiatric Diagnostic Manual Link to Drug Manufacturers.